



2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

New Orleans, LA – August 8, 2020

Conference Location	Hyatt Centric French Quarter	Phone: (504) 586-0800
	800 Iberville St New Orleans, LA	https://www.hyatt.com/en-US/hotel/louisiana/hyat centric-french-quarter-new-orleans/msyrf
Parking at the Conference	Reduced parking for all participants is available for \$12. Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk	
Driving Directions	Drive from I-10 E to New Orleans. Take exit 232 from I-10 E Continue on US-61 S. Take Tulane Ave to Iberville St Merge onto US-61 S/Airline Hwy Continue onto Tulane Ave Turn right onto Loyola Ave Turn left onto Gravier St Turn left onto O'Keefe Ave Continue onto Roosevelt Way and Continue onto Burgundy St Turn right onto Iberville St. The hotel is on the right	
Seminar Agenda and Syllabus Information	Registration and breakfast begin at 7:30 a.m. in the Orleans Room. Please check signage for any last minute room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. WiFi will be available without charge.	
7:30 am	Registration, Continental Breakfast & View Exhibits	
8:00 am	Opening Comments and Pre-Test	
8:20 am	 End Stage Liver Disease: Treatment, Managing Staging, workup, and diagnosis of cirrhosis Medical care of the patient with end stage Liver Transplantation Listing criteria, MELD scores, Exceptions Case Study 1 – Cirrhosis and Encephalopathy 	s liver disease
9:25 am	Hepatocellular Carcinoma (HCC)	
10:00 am	Break & View Exhibits	
10:15 am	 Hepatocellular Carcinoma: New Systemic Treatment Current FDA-Approved Therapies New chemotherapy regimens in development Immunotherapy as the new MoA for HCC 	

	Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma	
	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis	
11:00 am	Epidemiology of PSC and Ursodiol and Antibiotic Treatments	
	 Predicting outcomes and Improving Survival in PSC patients 	
	Causes and Markers of PBC	
	Ursodeoxycholic Acid (UDCA) and Obeticholic Acid	
11:40 am	Hepatology Update I – Viral Hepatitis	
11.40 am	• The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs	
12:00 pm	Luncheon and Educational Session "LAL-D: Lysosomal Acid Lipase Deficiency- Implementing	
	Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals	
12:55pm	Dessert and View Exhibits	
1:10pm	Hepatology Updates - Current/Emerging Topics in Liver Disease	
1:10piii	 Alcoholic Liver Disease, Liver Disease and Pregnancy, Hepatorenal Syndrome 	
	NAFLD, LAL-D and NASH	
	 Epidemiology, Demographics and Diagnosis 	
1:40 pm	• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.	
	 Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult 	
	Fatty Liver Disease	
2:15 pm	Break & View Exhibits	
	NASH Treatments in Practice and in Development	
	Current therapies for NASH	
2:30 pm	Lifestyle changes as a therapy	
	Drugs in clinical development for NASH	
	Case Study 3 - NASH Diagnosis and Treatment	
3:20 pm	Post-test and Wrap-Up	

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who "no show."

Recording and Photography

Attendance Policies

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0** *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.



SHOBHA JOSHI, MD

Dr. Joshi received her medical degree from the University of Bombay, India. After completing her Internal Medicine training at the Sinai Hospital of Baltimore and LSU Affiliated Program, she did her clinical and research Gastroenterology fellowship at Tulane University and the University of Pittsburgh. She was an Associate Professor of Medicine at St. Louis University School of Medicine, where in addition to doing basic research, she took care of liver transplant patients and general hepatology patients.

In December 2008, Dr. Joshi joined Ochsner Clinic Foundation as Director of Hepatology Research and Transplant Hepatologist where she has I incorporated the TeleECHO model to guide and educate providers on liver disease management, so they can manage their own patients for their hepatitis C or detection of Hepatocellular carcinoma





FREDRIC REGENSTEIN, MD

Fredric Regenstein, MD is the Medical Director of Liver Transplantation and a Professor of Clinical Medicine, Tulane University School of Medicine, New Orleans, Louisiana.

Dr. Regenstein received his MD degree from the Washington University School of Medicine. He completed his Internship and Residency in Medicine at Barnes Hospital, St. Louis, Missouri, and his Fellowship in Gastroenterology at Washington University School of Medicine.

Dr. Regenstein has more than 30 years of hepatology experience. His clinical and research interests include viral hepatitis, liver transplantation, and innovative therapies for hepatocellular carcinoma, cholestatic liver disease and nonalcoholic steatohepatitis. Dr. Regenstein is a Fellow of the American College of Gastroenterology and a member of the American Gastroenterological Association, AASLD, EASL, AST and the International Liver Transplant Society.



CYNTHIA BENZ DNP APRN

Cynthia Benz DNP APRN was certified as a Clinical Nurse Specialist in 1981. In her role as a CNS she has focused on the care of the chronically ill patient, with the last 18 years in Hepatology. She graduated with honors from Louisiana State University School of Medicine In New Orleans.

She is currently employed at the Southeast Louisiana Veterans Health Care System in GI/Hepatology. Additionally, Dr. Benz precepts graduate students from the University of South Alabama.